Abiomed (ABMD) Receives FDA Approval for Impella RP System

Abiomed Inc. (Nasdaq:ABMD) today announced that the Impella RP® (Right Percutaneous) System has received FDA approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval. Abiomed completed the HDE submission for the Impella RP in September 2014 […] View the full post at: Abiomed (ABMD) Receives FDA Approval for Impella RP System No related posts.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.